Ambu A/S (OTCMKTS:AMBBY – Get Free Report) and NeuroPace (NASDAQ:NPCE – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.
Risk & Volatility
Ambu A/S has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, NeuroPace has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500.
Valuation and Earnings
This table compares Ambu A/S and NeuroPace”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ambu A/S | $1.01 billion | 3.11 | $99.84 million | $0.37 | 35.95 |
| NeuroPace | $99.99 million | 2.59 | -$21.47 million | ($0.57) | -13.26 |
Ambu A/S has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Ambu A/S, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
78.8% of NeuroPace shares are held by institutional investors. 19.2% of NeuroPace shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Ambu A/S and NeuroPace’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ambu A/S | 9.90% | 10.47% | 8.34% |
| NeuroPace | -20.00% | -117.31% | -16.83% |
Analyst Ratings
This is a summary of recent ratings and price targets for Ambu A/S and NeuroPace, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ambu A/S | 0 | 1 | 0 | 0 | 2.00 |
| NeuroPace | 1 | 4 | 5 | 0 | 2.40 |
NeuroPace has a consensus price target of $15.50, suggesting a potential upside of 105.03%. Given NeuroPace’s stronger consensus rating and higher probable upside, analysts plainly believe NeuroPace is more favorable than Ambu A/S.
Summary
Ambu A/S beats NeuroPace on 8 of the 14 factors compared between the two stocks.
About Ambu A/S
Ambu A/S is a Danish medical-device company that develops, manufactures and markets equipment for hospitals and other healthcare settings. Its products are used in anesthesia, patient monitoring and diagnostics, and endoscopy. The company’s portfolio includes ventilation and resuscitation devices, electrodes and single-use endoscopes. Ambu is also known for the Ambu bag, a self-inflating resuscitation bag introduced in the 1950s. Founded in Denmark in 1937, Ambu serves healthcare professionals in markets around the world.
About NeuroPace
NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.
Receive News & Ratings for Ambu A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambu A/S and related companies with MarketBeat.com's FREE daily email newsletter.
